Sign inJoin waitlistJoin the waitlist

Charalampos Floudas

Co-Director · Clinical Center at the National Institutes of Health

Credentials: · · ·

History

Clinical Center at the National Institutes of Health
Present

National Institutes of Health
2019–2021
Hematology and Medical Oncology
Clinical Center at the National Institutes of Health
2016–2019
National and Kapodistrian University of Athens
2013–2016
University of Crete School of Medicine
1996–2000

Research

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
Review · Frontiers in Pharmacology · 2017 · 482 citations
Matching patients to clinical trials with large language models
Nature Communications · 2024 · 177 citations
The contemporary management of cancers of the sinonasal tract in adults
Review · Current Anthropology · 2023 · 113 citations

James Gulley
25 papers
Dara Bracken-Clarke
12 papers · 5 as a resident
Elisabetta Xue
11 papers · 11 as a resident
Fatima Karzai
11 papers
Nyall London
8 papers · 4 as a resident
Evrim Turkbey
7 papers
Jason Redman
7 papers
Julius Strauss
6 papers
Martha Quezado
5 papers
AC
Abhinav Chandra
4 papers
Clint Allen
4 papers
Heloisa Soares
4 papers

Clinical trials

Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Principal investigator · Not yet recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2026–2037
Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
Principal investigator · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
Principal investigator · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2030
Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2023–2030